• Preclinical demonstrated synergy of MK2206 with bendamustine (B) to induce CLL apoptosis.

• Phase 1 trial of MK2206 in combination with bendamustine and rituximab (BR) for relapsed/refractory CLL.

• Safety and efficacy of 3 dose levels.

• 1 week “run-in” of single agent MK2206 before initiation of BR during cycle 1.

• MK2206 then given along with BR on day 1 of cycles 2-6.

• Nine patients (median age 68) enrolled.

• Six had received prior chemoimmunotherapy.

• 5 had high risk disease defined as early progression within 26 months of last CIT.

• Three had received alemtuzumab containing regimen.

• Observed potent lymphocyte mobilization in all evaluated patients after one-dose .

• 90 mg once weekly dose determined to be MTD for phase 2 trial testing.

• 2 patients achieved complete response, one patient achieved nodular partial response and five patients achieved a partial response.

• Overall response rate (ORR) 89%.

• MK2206 in combination with BR well tolerated.

• Demonstrated promising results.

• Results compare favorably to BR alone in relapsed/refractory CLL patients.

Phase 2 testing of this combination is now underway.